EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome

P L Ortiz Romero, Y H Kim, K Molloy, P Quaglino iD, J Scarisbrick, S Thornton, K Sandilands, J E Dent, A Nixon iD, A Williams, M M Shinohara iD

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20357 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von P L Ortiz Romero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain. Hauptthemen laut MEDLINE: Quality of Life, Sezary Syndrome, Mycosis Fungoides, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kyowa Kirin Services Ltd, Galabank Business Park, Galashiels, Scotland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mycosis fungoides (MF) and Sézary syndrome (SS) are common subtypes of cutaneous T‐cell lymphoma that primarily affect the skin but may spread to the lymph nodes, viscera and blood. The symptom burden may compromise health‐related quality of life (HRQL). The phase 3 MAVORIC study ( ClinicalTrials.gov identifier NCT01728805) in patients with relapsed/refractory MF/SS reported improved HRQL with mogamulizumab compared with vorinostat.

Objectives

Use baseline (pre‐treatment) data from the MAVORIC study to describe the symptom burden of MF/SS and identify characteristics associated with worse HRQL.

Methods

Data were from 372 adults with stage IB–IVB histologically confirmed relapsed/ refractory MF or SS. Associations between demographic and medical history variables and worse HRQL (Skindex‐29, ItchyQol and Functional Assessment of Cancer Therapy – General [FACT‐G]) were determined by regression models.

Results

In the cohort of 372 adults, 70% were white; 42% were female; mean age was 63 (SD 13.0) years. Fifty‐five per cent had MF and 45% had SS; 77% had advanced (stage IIB–IV) disease, involving the skin in all patients and the blood and/or nodes in 66%. HRQL scores showed impairment versus normative means (where available), with the greatest impact on Symptoms and Emotions in the Skindex‐29, Functioning in the ItchyQol, and Functional Wellbeing in the FACT‐G. In regression analysis, worse HRQL across all domains and total score was associated with being female and younger, worse mSWAT score and worse itch for the Skindex‐29 ( n = 352), and being female, younger, Black/African American, worse performance status and worse itch for the ItchyQol ( n = 369). Associations across domains and total score were not found for the FACT‐G. Associations between domains and demographic/medical history were seen for all instruments.

Conclusions

The symptoms of advanced MF/SS compromise all HRQL domains. Treatment goals and therapeutic choice should be informed by individual patients' disease burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeSezary SyndromeMycosis FungoidesSkin NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain.
  • Stanford University School of Medicine and Cancer Institute, Stanford, CA, USA.
  • Tallaght University Hospital/Trinity College Dublin, Dublin, Ireland.
  • University of Turin, Turin, Italy.
  • University Hospital Birmingham, Birmingham, UK.
  • Susan Thornton, Cutaneous Lymphoma Foundation, Philadelphia, PA, USA.

ORCID-Profile: P Quaglino, A Nixon, M M Shinohara

Förderung

  • Kyowa Kirin Services Ltd, Galabank Business Park, Galashiels, Scotland

Zitieren

APA

Ortiz Romero, P. L., Kim, Y. H., Molloy, K., Quaglino, P., Scarisbrick, J., Thornton, S., Sandilands, K., Dent, J. E., Nixon, A., Williams, A., & Shinohara, M. M. (2025). Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20357

Vancouver

Ortiz Romero PL, Kim YH, Molloy K, Quaglino P, Scarisbrick J, Thornton S, et al. Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20357

BibTeX
@article{OrtizRomero2025,
  author = {Ortiz Romero, P L and Kim, Y H and Molloy, K and Quaglino, P and Scarisbrick, J and Thornton, S and Sandilands, K and Dent, J E and Nixon, A and Williams, A and Shinohara, M M},
  title = {Health‐related quality of life in cutaneous T‐cell lymphoma: A post hoc analysis of a phase 3 trial in mycosis fungoides and Sézary syndrome},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20357}
}
Kostenlos starten →